$PPCB RIPPING! 🚀 Up 149% Premarket 🔹 Propanc Biopharma is developing cancer treatments targeting recurrence and metastasis 🧬 🔹 Lead asset PRP focuses on pro

$PPCB RIPPING! 🚀 Up 149% Premarket 🔹 Propanc Biopharma is developing cancer treatments targeting recurrence and metastasis 🧬 🔹 Lead asset PRP focuses on proenzyme therapy for pancreatic, ovarian, and colorectal cancers 🎯 🔹 Recent updates include GMP production prep for a Phase 1b first-in-huma…